Last reviewed · How we verify
NCT05976516
CXCL2/CXCL8 Promote Intervertebral Disc Degeneration
trial testing CXCL2/CXCL8 in Cytokine in 40 participants. Status unknown.
30 March 2024
Quick facts
| Lead sponsor | Zhongda Hospital |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 40 |
| Start date | 1 August 2023 |
| Primary completion | 30 March 2024 |
| Estimated completion | 30 March 2024 |
| Sites | 1 location across China |
Drugs / interventions tested
- CXCL2/CXCL8
Conditions studied
- Cytokine — all drugs for Cytokine →
- Intervertebral Disc, Degenerative — all drugs for Intervertebral Disc, Degenerative →
Sponsor
Zhongda Hospital
Who can join
Eligibility, any sex, with Cytokine or Intervertebral Disc, Degenerative. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Low back pain (LBP) is the largest cause of morbidity in the world, and about 80% of Chinese people are affected in their lifetime. Although the prevalence of IDD gradually increases with age, IDD is very common among subjects under 30 years old. In addition to age, there are other factors, such as excessive or uneven mechanical load, obesity, genetics, nutrition, trauma and gender. In addition, it is not clear whether the heavy physical load associated with occupation is an important risk factor for IDD. Some studies have found that IDD is more common among athletes than the general population. Due to the complexity and multifactorial nature of IDD, its pathogenesis and risk factors are still unclear, which seriously hinders the rational stratification of LBP patients and limits the development of personalized treatment.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Unveiling the role of CXCL8/CXCR2 in intervertebral disc degeneration: A path to promising therapeutic strategies.
Xue P, Lv L, Liu L, Xu Y, et al · · 2024 · cited 6× · PMID 39444419 · DOI 10.1016/j.jot.2024.08.022
Verify or expand the search:
- PubMed search for NCT05976516
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Zhongda Hospital trials
Trials by the same sponsor.
- NCT07516704 — Safety and Efficacy of Docetaxel, Darolutamide, and Homoharringtonine Combined With Androgen Deprivation Therapy in Neoa · EARLY_PHASE1 · not yet recruiting
- NCT07504731 — Trunk Inclination, Positive End-expiratory Pressure, and Lung Recruitability · recruiting
- NCT07351669 — A Multicenter Prospective Study on the Performance of Spectral CT for Evaluating Treatment Response After TACE in Hepato · recruiting
- NCT07311915 — Propranolol Combined With Novel Endocrine Therapy and Androgen Deprivation Therapy (ADT) for Neoadjuvant Treatment in Hi · NA · not yet recruiting
- NCT07585877 — Effect of Branched-Chain Amino Acid Supplementation on Myopia Progression · NA · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05976516 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Zhongda Hospital
- Last refreshed: 4 August 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05976516.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing